Vera Therapeutics' Trutakna Wins FDA Accelerated Approval in IgAN: 46% Proteinuria Reduction, $519M Net Cash, and a Q3 Confirmatory Bar

The FDA granted accelerated approval to Vera Therapeutics' TRUTAKNA (atacicept-vymj) on July 7, 2026. The number that defined the filing: a 46% reduction from baseline in proteinuria, drawn from a prespecified interim analysis of the ongoing ORIGIN 3 trial.

That 46% figure outpaced the placebo group by 42 percentage points after 36 weeks. ORIGIN 3 enrolled 431 adults with biopsy-confirmed IgAN, randomized 1:1 to atacicept 150 mg or placebo, self-administered weekly via at-home subcutaneous autoinjector, per Vera's July 7 press release on GlobeNewswire.

TRUTAKNA's mechanism is its differentiating claim: it is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers of IgAN at the source, per that same release. The drug also carried Priority Review and Breakthrough Therapy designation into the decision.

"The approval of TRUTAKNA as the first and only BAFF and APRIL inhibitor for IgAN marks an important milestone," Vera Therapeutics founder and CEO Marshall Fordyce said in the company's July 7 press release.

The disease context is not incidental. IgAN is the leading cause of chronic kidney disease or failure worldwide. It is diagnosed most often in people between 30 and 40 years of age, and at least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis, per the same press release.

Accelerated approval is a conditional designation. Vera plans to use ORIGIN 3's eGFR readout — now accelerated to Q3 2026 — as confirmatory data, with a supplemental BLA submission targeted for Q4 2026, per Vera's July 7 press release.

Trutakna enters as the sixth drug approved for IgAN. Novartis' complement inhibitor Fabhalta is already approved in the indication. Vertex Pharmaceuticals submitted an accelerated application for povetacicept in June 2026. Otsuka is also active in the space, per BioSpace reporting dated July 7, 2026.

Safety signals from the trial are part of the record: infections were reported in 32% of Trutakna recipients versus 28% on placebo; injection-site reactions occurred in 30% versus 5%, per Vera's press release.

On the balance sheet, Vera's Q1 2026 SEC filing shows $596.76 million in cash and $76.89 million in debt, a net cash position of $519.87 million, or $7.24 per share, on 71.78 million shares outstanding. In February 2026, the company disclosed completion of an equity financing and a debt agreement with combined potential gross proceeds of $800 million, specifically to fund operations beyond potential approval and U.S. commercial launch of atacicept, per that filing.

Vera's shares closed up 7% at $42.96 on the trading day following the July 7 announcement, per the company's press release.

The broader market for the week ending July 24, 2026 was mixed. The S&P 500 rose less than 0.1% Friday, the Dow Jones Industrial Average added 0.5%, and the Nasdaq composite fell 0.6%, with all three indexes finishing the week lower, per AP reporting via King5. The Russell 2000 is up 19.4% year-to-date versus the Nasdaq's 9.8% rise, per the same source.

The next scheduled event on Vera's regulatory calendar: the ORIGIN 3 eGFR confirmatory readout in Q3 2026, followed by the targeted supplemental BLA submission in Q4 2026, per Vera's July 7 press release.